Skip to main content
Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Fig. 2

Univariate model of abatacept discontinuation. Results are presented for variables retained in the model at the 20 % level. HRs are presented with corresponding 95 % CIs. An HR >1 indicates an increased risk of abatacept discontinuation. An HR <1 indicates a decreased risk of abatacept discontinuation. HRs are significant when the 95 % CIs do not overlap 1. The patient population included 17 patients who were anti-TNF naïve and who had previously received treatment with a biologic with a different mechanism of action. CCP, cyclic citrullinated peptide; cDMARD, conventional disease-modifying anti-rheumatic drug; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; HR, hazard ratio; MTX, methotrexate; RF, rheumatoid factor; TNF, tumor necrosis factor

Back to article page
\